Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018089690) SYSTEMS, DEVICES, AND METHODS FOR ELECROPORATION INDUCED BY MAGNETIC FIELDS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

1. A system, comprising:

a control device; and

a magnetic device coupled to the control device, the magnetic device configured to magnetically couple to a treatment target including one or more cells exposed to an agent, the magnetic device including one or more magnetic coils,

the control device and the magnetic device collectively configured to generate and apply a transient magnetic field to the treatment target to porate the one or more cells and to permit the agent to enter the one or more cells.

2. The system of claim 1, the transient magnetic field configured to induce an electric field in the treatment target to porate the one or more cells.

3. The system of claim 1, the control device including a set of independent circuits, the magnetic device is a first magnetic device of a set of magnetic devices, each magnetic device of the set of magnetic devices including one or more magnetic coils,

wherein the transient magnetic field is a first transient magnetic field of a set of transient magnetic fields,

wherein the control device and the set of magnetic devices are collectively configured to generate and apply the set of transient magnetic fields to the treatment target.

4. The system of claim 3, further comprising a user interface configured to receive an indication of spatial information associated with application of the set of transient magnetic fields, the control device and the set of magnetic devices collectively configured to generate and apply the set of transient magnetic fields based on the indication of spatial information.

5. The system of claim 3, wherein each magnetic device of the set of magnetic devices is independently addressable by a corresponding circuit of the set of independent circuits.

6. The system of claim 1, the control device including a signal generator configured to apply an electrical signal to the magnetic device.

7. The system of claim 6, the signal generator selected from the group consisting of an oscillator, a frequency synthesizer, a sine-wave generator, a pulse generator, a random noise generator, an arbitrary waveform generator, and combinations thereof.

8. The system of claim 1, wherein the magnetic device includes a ferromagnetic circuit element as an inductor.

9. The system of claim 6, wherein the electrical signal is selected from the group consisting of a pulsed ¼ sine wave, followed by an L/R decay, a sine wave, a decaying sine wave, a square wave, and an arbitrary waveform.

10. The system of claim 1, wherein the magnetic device includes a superconducting electromagnet configured to generate the transient magnetic field.

11. The system of claim 1, wherein the one or more magnetic coils of the magnetic device are configured to encircle at least a portion of the treatment target during use.

12. The system of claim 1, wherein the one or more magnetic coils are one or more oscillating antennae.

13. The system of claim 12, wherein each oscillating antenna of the set of oscillating antennae is independently addressable.

14. The system of claim 1, wherein the transient magnetic field defines a treatment volume of at least about 100 μΐ,.

15. The system of claim 1, wherein the transient magnetic field is configured to reversibly porate the one or more cells to permit the agent to enter the one or more cells.

16. The system of claim 1, wherein the treatment target includes a container.

The system of claim 1, wherein the treatment target includes a medical device.

18. The system of claim 1, wherein the treatment target includes a mammalian target.

19. The system of claim 1, wherein the one or more cells are in vitro.

20. The system of claim 1, wherein the one or more cells are in vivo.

21. The system of claim 1, wherein the one or more cells are ex vivo.

22. The system of claim 1, wherein the one or more cells are mammalian cells.

23. The system of claim 22, wherein the mammalian cells are selected from the group consisting of heart cells, liver cells, kidney cells, skin cells, brain cells, bladder cells, testes cells, ovary cells, uterus cells, eye cells, pancreatic cells, fallopian tube cells, vaginal cells, teste cells, prostate cells, placenta cells, large intestine cells, small intestine cells, colon cells, cancer cells, muscle cells, epithelial cells, connective tissue cells, nerve cells, blood cells, white blood cells, red blood cells, T cells, B cells, lymphocytes, antigen presenting cells, platelets, macrophages, monocytes, granulocytes neutrophils, eosinophils, basophils, and cancer cells.

24. The system of claim 23, wherein the cancer cells are pre-metastatic cancer cells or metastatic cancer cells.

25. The system of claim 1, wherein the one or more cells are bacterial cells.

26. The system of claim 1, wherein the one or more cells are fungal cells.

27. The system of claim 1, wherein the one or more cells are parasite cells.

28. The system of claim 1, wherein the one or more cells are plant cells.

29. The system of claim 1, wherein the agent is a nucleic acid.

30. The system of claim 24, wherein the nucleic acid is selected from the group consisting of DNA, RNA, siRNA, shRNA, miRNA, mtDNA, and DNA/RNA hybrids.

31. The system of claim 30, wherein the nucleic acid is associated with an exosome, a polypeptide, viral vector, or artificial chromosome.

32. The system of claim 29, wherein the nucleic acid comprises one or more genes, open reading frames, or fragments.

33. The system of claim 1, wherein the agent is a polypeptide, mutant polypeptide, or fragment thereof.

34. The system of claim 33, wherein the nucleic acid encodes a polypeptide, mutant polypeptide, or fragment thereof.

35. The system of claim 34, wherein the polypeptide is selected from the group consisting of an enzyme, a ligand, a receptor, a structural protein, and a fusion protein.

36. The system of claim 34, wherein the polypeptide is an antigenic polypeptide.

37. The system of claim 36, wherein the antigenic polypeptide is from a mammalian cell, a bacteria, virus, parasite, or fungus.

38. The system of claim 37, wherein the mammalian cell is a cancer cell.

39. The system of claim 38, wherein the cancer cell antigenic peptide is associated with a hematologic malignancy or a solid tumor.

40. The system of claim 38, wherein the cancer cell antigenic peptide is a tumor antigen or a tumor-associated antigen.

41. The system of claim 34, wherein the polypeptide is selected from the group consisting of a ligand, an antigen-binding moiety, a receptor, a ligand-receptor fusion, antibody, and a fragment thereof.

42. The system of claim 41, wherein the antibody or fragment thereof is selected from the group consisting of a monoclonal antibody, polyclonal antibody, chimeric antibody, humanized antibody, scFv, VL, VH, CL, CHI domain, F(ab)2 fragment, a bivalent antibody, a Fd fragment, or a Fv fragment.

43. The system of claim 1, wherein the agent is a conjugated drug or molecule.

44. The system of claim 43, wherein the conjugated drug or molecule is radioimmunotherapy (RIT), antibody-directed enzyme prodrug therapy (ADEPT) or an antibody-drug conjugate.

45. The system of claim 1, wherein the agent is a drug.

46. The system of claim 45, wherein the drug is a chemotherapeutic drug, pro-apoptotic drug, biologic drug, antibiotic, anti-fungal drug, ACE inhibitor, steroid, immunosuppressant, immunostimulant, immunomodulatory, anti-inflammatory, or an anti-fibrotic drug.

47. A method, comprising:

exposing one or more cells in a treatment target to an agent; and

applying a transient magnetic field to the treatment target to porate the one or more cells and to permit the agent to enter the one or more cells.

48. The method of claim 47, the transient magnetic field configured to induce an electric field in the treatment target to porate the one or more cells.

49. The method of claim 47, wherein the transient magnetic field is a first transient magnetic field of a set of transient magnetic fields, the applying further including applying the set of transient magnetic fields to the treatment target.

50. The method of claim 49, further comprising receiving an indication of spatial information associated with application of the set of transient magnetic fields, the applying further including applying the set of transient magnetic fields based on the indication of spatial information.

51. The method of claim 47, further comprising generating the transient magnetic field by applying an electrical signal to a magnetic device that is inductively coupled to the treatment target.

52. The method of claim 51, wherein the electrical signal is selected from the group consisting of a pulsed ¼ sine wave followed by an L/R decay, a sine wave, a decaying sine wave, a square wave, and an arbitrary waveform.

53. The method of claim 47, further comprising generating the transient magnetic field via a magnetic coil.

54. The method of claim 47, further comprising generating the transient magnetic field via a superconducting electromagnet.

55. The method of claim 47, further comprising generating the transient magnetic field via a magnetic coil encircling at least a portion of the treatment target.

56. The method of claim 47, further comprising generating the transient magnetic field via a set of magnetic coils.

57. The method of claim 56, wherein each magnetic coil of the set of magnetic coils is independently addressable.

58. The method of claim 47, wherein the transient magnetic field defines a treatment volume of at least about 100

59. The method of claim 47, wherein the transient magnetic field is configured to reversibly porate the one or more cells to permit the agent to enter the one or more cells.

60. The method of claim 47, wherein the treatment target includes a container.

61. The method of claim 47, wherein the treatment target includes a medical device.

62. The method of claim 47, wherein the treatment target includes a mammalian target.

63. The method of claim 47, wherein the one or more cells are in vitro.

64. The method of claim 47, wherein the one or more cells are in vivo.

65. The method of claim 47, wherein the one or more cells are ex vivo.

66. The method of claim 47, further comprising:

extracting the one or more cells from a patient into the treatment target; and

after applying the magnetic field, reintroducing the one or more cells into the patient.

67. The method of claim 47, wherein the one or more cells are mammalian cells.

68. The method of claim 67, wherein the mammalian cells are selected from the group consisting of heart cells, liver cells, kidney cells, skin cells, brain cells, bladder cells, testes cells, ovary cells, uterus cells, eye cells, pancreatic cells, fallopian tube cells, vaginal cells, teste cells, prostate cells, placenta cells, large intestine cells, small intestine cells, colon cells, cancer cells, muscle cells, epithelial cells, connective tissue cells, nerve cells, blood cells, white blood cells, red blood cells, T cells, B cells, lymphocytes, antigen presenting cells, platelets, macrophages, monocytes, granulocytes neutrophils, eosinophils, basophils, and cancer cells.

69. The method of claim 68, wherein the cancer cells are pre-metastatic cancer cells or metastatic cancer cells.

70. The method of claim 47, wherein the one or more cells are bacterial cells.

71. The method of claim 47, wherein the one or more cells are fungal cells.

72. The method of claim 47, wherein the one or more cells are parasite cells.

73. The method of claim 47, wherein the one or more cells are plant cells.

74. The method of claim 47, wherein the agent is a nucleic acid.

75. The method of claim 74, wherein the nucleic acid is selected from the group consisting of DNA, RNA, siRNA, shRNA, miRNA, mtDNA, and a DNA/RNA hybrid.

76. The method of claim 75, wherein the nucleic acid is associated with an exosome, a polypeptide, viral vector, or artificial chromosome.

77. The method of claim 75, wherein the nucleic acid comprises one or more genes, open reading frames, or fragments.

78. The method of claim 47, wherein the agent is a polypeptide, mutant polypeptide, or fragment thereof.

79. The method of claim 74, wherein the nucleotide encodes a polypeptide, mutant polypeptide, or fragment thereof.

80. The method of claim 79, wherein the polypeptide or fragment thereof is selected from the group consisting of an enzyme, a ligand, a receptor, a structural protein, and a fusion protein.

81. The method of claim 79, wherein the polypeptide is an antigenic polypeptide.

82. The method of claim 81, wherein the antigenic polypeptide is from a mammalian cell, a bacteria, virus, parasite, or fungus.

83. The method of claim 82, wherein the mammalian cell is a cancer cell.

84. The method of claim 83, wherein the cancer cell antigenic peptide is associated with a hematologic malignancy or a solid tumor.

85. The method of claim 84, wherein the cancer cell antigenic peptide is a tumor antigen or a tumor-associated antigen.

86. The method of claim 83, wherein the polypeptide is a ligand, an antigen-binding moiety, a receptor, a ligand-receptor fusion, antibody, or a fragment thereof.

87. The method of claim 86, wherein the antibody or fragment thereof is selected from the group consisting of a monoclonal antibody, polyclonal antibody, chimeric antibody, humanized antibody, scFv, VL, VH, CL, CHI domain, F(ab)2 fragment, a bivalent antibody, a Fd fragment, and a Fv fragment.

88. The method of claim 47, wherein the agent is a conjugated drug or molecule.

89. The method of claim 88, wherein the conjugated drug or molecule is radioimmunotherapy (RIT), antibody-directed enzyme prodrug therapy (ADEPT) or an antibody-drug conjugate.

90. The method of claim 47, wherein the agent is a drug.

91. The method of claim 90, wherein the drug is a chemotherapeutic drug, pro-apoptotic drug, biologic drug, antibiotic, anti-fungal drug, ACE inhibitor, steroid, immunosuppressant, immunostimulant, immunomodulatory, anti-inflammatory, or an anti-fibrotic drug.

92. The method of claim 47, wherein the one or more cells are reintroduced into the patient in an amount effective to treat a disease or disorder in the patient.

93. The method of claim 92, wherein the patient is human.

94. The method of claim 92, wherein the disease or disorder is an infection, a hereditary disorder, an environmentally-influenced disease or disorder, an autoimmune disease, or cancer.

95. A system, comprising:

a control device; and

a magnetic device coupled to the control device, the magnetic device configured to inductively couple to a treatment target including one or more cells exposed to an agent, the magnetic device including one or more magnetic coils,

the control device and the magnetic device collectively configured to generate and apply a transient magnetic field to the treatment target to induce an electric fieldin the treatment target and to permit the agent to enter the one or more cells.

97. A system, comprising:

a control device including two or more circuits; and

a set of magnetic devices coupled to the control device, each magnetic device of the set of magnetic devices configured to magnetically couple to the treatment target including one or more cells exposed to an agent, each magnetic device of the set of magnetic devices including two or more magnetic coils, each magnetic coil associated with a different circuit of the control device, the control device and the set of magnetic devices collectively configured to generate and apply two or more transient magnetic fields to the treatment target to induce an electric field in the treatment target to permit the agent to enter the one or more cells.